Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age19+
SponsorKyowa Kirin Co., Ltd.
About this trial
The purpose of this surveillance is to assess the safety and efficacy of Poteligeo Inj. 20 mg (mogamulizumab) in routine clinical settings.
Eligibility criteria
Qualifiers
Adults 19 years of age or older
Individuals who are confirmed to have received administration of the study drug for the purpose of "the treatment for adult patients with fungoidal granuloma or Sezary syndrome who have received one or more systemic therapies," or who are considered to require administration of the study drug in the investigator's opinion
Individuals who (or whose legally acceptable representatives) signed the Consent to Use of Personal Information of their own free will for participation in this use-result surveillance
Disqualifiers
Patients with hypersensitivity to any ingredients of this drug
Patients who intend to use this drug for non-approved indications
Patients who participated in a pre-market clinical trial of the study drug and received administration of the study drug
Trial design
Treatments tested in this trial
- Poteligeo 20mg
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov